Sanofi

Scaling Artificial Intelligence in Healthcare

Learn more about Sanofi at VivaTech 2026

Our Latest Articles

Shuang Yang, Scientist, China, working in a laboratory with automated scientific equipment, wearing a white lab coat, facing away from the camera.

AI in Healthcare

June 16, 2026

VivaTech 2026: Scaling Artificial Intelligence in Healthcare to Deliver Faster for Patients

Two women in black wetsuits standing on a beach with a surfboard, ready for surfing

The Power of Chasing A Dream

Every day, we chase the miracles of science to improve people’s lives. We apply our deep understanding of the immune system to develop breakthrough innovations in medicines and vaccines so you can focus on what matters most, chasing your dreams. If you’re chasing your dreams, remember... you’re not alone. We’re right beside you

 

People Stories

We’re proud to spotlight those who inspire us to keep going further in the work we do.

A woman wearing a black wetsuit holds a surfboard under blue skies and sunshine while looking out to the horizon with a hopeful and determined expression.​

Céline, living with secondary progressive multiple sclerosis

France

We are an R&D driven, AI-powered biopharmaceutical company committed to improving people’s lives and delivering compelling growth

About Us

Who We Are

We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Our Pipeline

5

Therapeutic areas

77

Compounds in clinical development

21

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


June 23, 2026
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

June 22, 2026
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

June 19, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma